



Final Appraisal Recommendation

Tenofovir disoproxil fumarate (Viread[®]▼)

**Submission by:
Gilead Sciences Ltd**

Advice No: 1411 – October 2011

Recommendation of AWMSG

Tenofovir disoproxil fumarate (Viread[®]▼) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B (CHB) in adults with decompensated liver disease.

Treatment should normally be initiated following dialogue with a specialist liver unit.

AWMSG is of the opinion that tenofovir disoproxil fumarate (Viread[®]▼) is not suitable for shared care within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: